Other products

ADV6209

ADV6209 is an oral liquid solution developed by Advicenne for moderate sedation.

ADV6209 has been specially designed for children to significantly reduce their anxiety and to improve their immobility when they have to undertake stressfull or painfull medical, therapeutic or diagnostic procedures. If approved, it would be the only oral midazolam in liquid form which would be suitable and indicated for children above 6 months.

 

The product was originally developed in collaboration with Amiens’s public hospital (University Hospital).

In March 2016, Advicenne sold ADV6209 to the Swiss company Primex Pharmaceuticals in a global deal worth several tens of millions of euros with a significant upfront payment and subsequent milestones and royalties.

Likozam®

Advicenne has been commercialising Likozam, a product in-licensed from Rosemont, in France since February 2016. Likozam is designed to meet the unmet medical need of patients with partial and generalised chronic refractory epilepsy.

Likozam can be used to treat partial and generalised chronic refractory epilepsy in children and adults. It is the only product available on the market for refractory epilepsy in a liquid form that is suitable and indicated for children below 6 years old and people with swallowing difficulties.

Summary of the transparency committee opinion

Levidcen®

Advicenne has been commercialising Levidcen, a product in-licensed from Desitin GmbH, in France since October 2015. It is used to address the unmet medical need of epileptic patients with partial onset seizures.

Levidcen is a granulated (2 mm) formulation of levetiracetam designed to treat epilepsy in children and adults. Levidcen is tasteless and has been specifically adapted for children and patients with swallowing difficulties. Other formulations of levetiracetam are either liquids with a very bad taste which can reduce patient compliance or big tablets of approximately 13-19mm which are not suitable for patients with swallowing difficulties.

Summary of the transparency committee opinion